Institutional Review Board Barriers and Solutions Encountered in the Collaboration Among Pharmacists and Physicians to Improve Outcomes Now Study: A National Multicenter Practice-Based Implementation Trial

To categorize institutional review board (IRB) challenges and solutions encountered in a multicenter, practice-based research network (PBRN) study and to assess the impact of IRB requirements on individual principal investigators’ (PIs’) willingness to participate in future PBRN studies

Muon spin rotation measurements of the superfluid density in fresh and aged superconducting PuCoGa5_5

We have measured the temperature dependence and magnitude of the superfluid density $\rho_{\rm s}(T)$ via the magnetic field penetration depth $\lambda(T)$ in PuCoGa$_5$ (nominal critical temperature $T_{c0} = 18.5$ K) using the muon spin rotation technique in order to investigate the symmetry of the order parameter, and to study the effects of aging on the superconducting properties of a radioactive material. The same single crystals were measured after 25 days ($T_c = 18.25$ K) and 400 days ($T_c = 15.0$ K) of aging at room temperature. The temperature dependence of the superfluid density is well described in both materials by a model using d-wave gap symmetry. The magnitude of the muon spin relaxation rate $\sigma$ in the aged sample, $\sigma\propto 1/\lambda^2\propto\rho_s/m^*$, where $m^*$ is the effective mass, is reduced by about 70% compared to fresh sample. This indicates that the scattering from self-irradiation induced defects is not in the limit of the conventional Abrikosov-Gor'kov pair-breaking theory, but rather in the limit of short coherence length (about 2 nm in PuCoGa$_5$) superconductivity.Comment: 11 page

A first update on mapping the human genetic architecture of COVID-19

peer reviewe

Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes

Artavazd Tadevosyan1, Eric J MacLaughlin2, Vardan T Karamyan31Departments of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, QC, Canada; 2Department of Pharmacy Practice, 3Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USAAbstract: Hypertension in the elderly is one of the main risk factors of cardiovascular and cerebrovascular diseases. Knowledge regarding the mechanisms of hypertension and specific considerations in managing hypertensive elderly through pharmacological intervention(s) is fundamental to improving clinical outcomes. Recent clinical studies in the elderly have provided evidence that angiotensin II type 1 (AT1) receptor antagonists can improve clinical outcomes to a similar or, in certain populations, an even greater extent than other classical arterial blood pressure-lowering agents. This newer class of antihypertensive agents presents several benefits, including potential for improved adherence, excellent tolerability profile with minimal first-dose hypotension, and a low incidence of adverse effects. Thus, AT1 receptor antagonists represent an appropriate option for many elderly patients with hypertension, type 2 diabetes, heart failure, and/or left ventricular dysfunction.Keywords: angiotensin II, ARB, cardiovascular disease, antihypertensive therapy, elderl